Pediatrix Medical Group Inc

Pediatrix Medical Group Inc(MD)の株式分析

$27.760

+0.719 (+2.59%)終値時点

Loading chart…
高値
27.780
始値
27.285
出来高加重平均価格
27.61
出来高
479.09K
時価総額
607.54M
安値
27.285
売買代金
13.23M
EV/EBITDA(TTM)
8.52

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice.

www.pediatrix.com

AI分析 of Pediatrix Medical Group Inc (MD)

中立

Pediatrix Medical Group Inc is currently trading at $26.64, which is close to the average analyst price target of $28, suggesting limited upside potential. The RSI is at 68.631, indicating it is approaching overbought territory, which could lead to a price correction. Additionally, the stock has shown a strong year-to-date change of +25.13% and a one-year change of +65.98%, but the recent downgrade from Jefferies highlights potential risks ahead, particularly with earnings growth expected to cap due to tax credit headwinds.

アナリスト評価(14)

-15.35% 下落余地
中立
3 買い
10 中立
1 売り
現在: 27.76
安値
23.00
平均
23.50
高値
24.00

Jefferies

2026-08-19

目標株価

$28

中立

UBS

2026-08-06

目標株価

$28

中立

Deutsche Bank

2026-08-05

目標株価

$25

中立

UBS

2026-05-12

目標株価

$25

中立

Mizuho

2026-05-08

目標株価

$24

中立

バリュエーション指標

Pediatrix Medical Group Inc(MD)の現在の予想PERは9.29で、5年平均は9.36です。

予想PER

適正
5年平均 P/E
9.36
現在のP/E
9.29
割高
11.67
割安
7.04

予想EV/EBITDA

適正
5年平均 EV/EBITDA
8.02
現在のEV/EBITDA
8.52
割高
9.65
割安
6.39

予想PSR

割高
5年平均 P/S
0.71
現在のP/S
1.08
割高
0.96
割安
0.47

Alphio AI による MD の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%MD

$14.32

シナリオ価格

基

基本

基本 · 50%MD

$11.56

シナリオ価格

弱

弱気

弱気 · 25%MD

$9.40

シナリオ価格

MD を保有するクジラ

D

Dana Investment Advisors Inc

+ を保有MD

+4.91%

3か月リターン

A

Applied Finance Advisors, LLC

+ を保有MD

-1.66%

3か月リターン

イベントタイムライン

2026-08-04 (ET)

06:30:00

Pediatrix Medical Sees 2026 Adjusted EBITDA of $280M-$300M

06:30:00

Company Reports Q2 Revenue of $487.8M, Exceeds Expectations

2026-07-15 (ET)

07:00:00

Pediatrix Medical Group Confirms Stable Q2 2026 Business Trends

2026-05-05 (ET)

06:20:00

Pediatrix Medical Reaffirms FY26 Adjusted EBITDA View of $280M-$300M

06:10:00

Pediatrix Medical Group Q1 Revenue Reaches $476M

ニュース

MD のよくある質問 — Alphio AI が回答

Pediatrix Medical Group, Inc. is a provider of physician services, including newborn, maternal-fetal, and other pediatric subspecialty care. The Company’s affiliated clinicians provide services to women, babies and children across the continuum of care, both in hospital settings and office-based practices. Its specialties include obstetrics, maternal-fetal medicine and neonatology, complemented by pediatric subspecialties. It offers specialized and critical care services through approximately 4,400 affiliated physicians and other clinicians. It provides neonatal clinical care, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications. The Company provides maternal-fetal and obstetrical medical care to expectant mothers experiencing complicated pregnancies primarily in areas where its affiliated neonatal physicians practice. It operates in the Healthcare sector (SERVICES-HOSPITALS industry).

Pediatrix Medical Group Inc is currently trading at $26.64, which is close to the average analyst price target of $28, suggesting limited upside potential. The RSI is at 68.631, indicating it is approaching overbought territory, which could lead to a price correction. Additionally, the stock has shown a strong year-to-date change of +25.13% and a one-year change of +65.98%, but the recent downgrade from Jefferies highlights potential risks ahead, particularly with earnings growth expected to cap due to tax credit headwinds.

14 analysts cover MD: 3 rate it Buy, 10 Hold and 1 Sell. The average price target is 23.50.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める